AstraZeneca Pharma India · NSE: ASTRAZEN · BSE: 506820
Q3 FY22 results · Oct–Dec 2021
AstraZeneca Pharma India reported revenue from operations of ₹200.53 crore (up 0.1% from Q3 FY21) and net profit of ₹11.42 crore (down 45.8% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a standalone basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 200.53 | 200.25 | +0.1% | 197.71 | +1.4% |
| Other income | 5.33 | 2.93 | +82.0% | 2.84 | +87.5% |
| Total income | 205.86 | 203.18 | +1.3% | 200.55 | +2.6% |
| Profit before tax | 16.26 | 28.30 | −42.5% | 16.24 | +0.2% |
| Net profit for the period | 11.42 | 21.05 | −45.8% | 11.95 | −4.4% |
| EPS, basic (₹) | 4.57 | 8.42 | −45.8% | 4.78 | −4.4% |
| Net margin (%) | 5.7 | 10.5 | 6.0 |
Standalone
- Filed with BSE
- 09 Feb 2022, 15:56 IST
- Board meeting
- 08 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE